Zydus Pharmaceuticals USA Inc. received FDA approval for oral Methotrexate under ANDA207812, marking a potential new generic entry into a crowded market segment where increasing competition will likely drive price pressures on the therapeutic.
Zydus Pharmaceuticals USA Inc. received FDA approval for oral Methotrexate under ANDA207812, marking a potential new generic entry into a crowded market segment where increasing competition will likely drive price pressures on the therapeutic.